Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Comparative, Proof of Concept Study, Comprising of a Pilot Phase Bioavailability Study Part and a Randomised, Cross-over Food-effect Study Part of 'XS003' and Originator in Healthy Male Subjects

Next Previous
Trial Profile

A Comparative, Proof of Concept Study, Comprising of a Pilot Phase Bioavailability Study Part and a Randomised, Cross-over Food-effect Study Part of 'XS003' and Originator in Healthy Male Subjects

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 10 Jul 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nilotinib (Primary)
  • Indications Chronic myeloid leukaemia; Eosinophilia; Gastrointestinal stromal tumours; Malignant melanoma; Precursor cell lymphoblastic leukaemia-lymphoma; Skin cancer
  • Focus Pharmacokinetics; Proof of concept
  • Sponsors XSpray Microparticles; Xspray Pharma

Most Recent Events

  • 09 Jul 2024 According to a Xspray Pharma AB media release, company announced today new clinical data from its XS003 registration study program. In the announced study, XS003 demonstrates matching bioavailability to Tasigna, with a 50% reduced dose.
  • 09 Jul 2024 Results published in a Xspray Pharma AB media release
  • 10 Nov 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top